Sign In
Buy ANIP
$75.23
+0.580 (+0.777%)
At Close: Jun 03, 2026
ANI Pharmaceuticals, Inc. (ANIP) Q3 2025 Earnings Call Transcript
02:16pm, Friday, 07'th Nov 2025
ANI Pharmaceuticals, Inc. ( ANIP ) Q3 2025 Earnings Call November 7, 2025 8:30 AM EST Company Participants Nikhil Lalwani - President, CEO & Director Christopher Mutz - Senior Vp & Head of Rare Diseas
Compared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key Metrics
10:31am, Friday, 07'th Nov 2025
Although the revenue and EPS for ANI (ANIP) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street
ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Beat Estimates
09:05am, Friday, 07'th Nov 2025
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $1.74 per share. This compares to earnings of $1.34 per share a year ago.
ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance
06:50am, Friday, 07'th Nov 2025
Record quarterly net revenues of $227.8 million, an increase of 53.6% year-over-year Purified Cortrophin® Gel net revenues of $101.9 million, an increase of 93.8% year-over-year Record quarterly adju
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:51am, Friday, 31'st Oct 2025
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
ANI Pharmaceuticals: Strong Buy On Rare Disease Growth, Record Of Beating Estimates
05:54pm, Tuesday, 28'th Oct 2025
In my opinion, ANI Pharmaceuticals should beat earnings and revenue estimates for the 13th consecutive quarter. Purified Cortrophin sales should lead the way. ANIP should announce approval and marketi
ANI Pharmaceuticals to Report Q3 Earnings: Is a Beat in the Cards?
01:45pm, Monday, 27'th Oct 2025
ANIP's rising Cortrophin Gel sales and new rare disease products, along with generic and other segments, could power another earnings beat this quarter.
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
01:45pm, Monday, 27'th Oct 2025
ANI (ANIP) possesses solid growth attributes, which could help it handily outperform the market.
Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?
10:41am, Monday, 27'th Oct 2025
Here is how ANI Pharmaceuticals (ANIP) and Cognition Therapeutics, Inc. (CGTX) have performed compared to their sector so far this year.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:51am, Monday, 27'th Oct 2025
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET
06:50am, Friday, 24'th Oct 2025
PRINCETON, N.J., Oct. 24, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its third quarter 2025 financial results
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Recommendation of “Moderate Buy” from Analysts
01:59am, Thursday, 23'rd Oct 2025
Shares of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP - Get Free Report) have been assigned an average rating of "Moderate Buy" from the ten analysts that are covering the firm, MarketBeat Ratings reports
ANI (ANIP) Upgraded to Strong Buy: Here's Why
01:01pm, Thursday, 16'th Oct 2025
ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Presentation at AAO 2025 part of ongoing NEW DAY data dissemination at medical meetings Presentation at AAO 2025 part of ongoing NEW DAY data dissemination at medical meetings
Why ANI (ANIP) Could Beat Earnings Estimates Again
01:11pm, Wednesday, 15'th Oct 2025
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
